Blood Research

WFH guidelines, practice patterns: peak plasma factor levels and duration of administration [5].

Type of hemorrhage Hemophilia A
Lower- dose practice pattern Higher- dose practice pattern
Peak factor
level (IU/dL)
Treatment
duration (d)
Peak factor
level (IU/dL)
Treatment
duration (d)
Joint 10–20 1–2a) 40–60 1–2
Superficial muscle/no NV compromise (except iliopsoas) 10–20 2–3a) 40–60 2–3a)
Iliopsoas or deep muscle with NV injury or substantial blood loss
Initial 20–40 1–21 80–100 1–2
Maintenance 10–20 3–5b) 30–60 3–5b)
Intracranial
Initial 50–80 1–3 80–100 1–7
Maintenance 20–40 8–14 50 8–21
30–50 4–7 - -
Throat and neck
Initial 30–50 1–3 80–100 1–7
Maintenance 10–20 4–7 50 8–14
Gastrointestinal
Initial 30–50 1–3 80–100 7–14
Maintenance 10–20 4–7 50
Renal 20–40 3–5 50 3–5
Deep laceration 20–40 5–7 50 5–7
Surgery (major)
Pre-op 60–80 80–100
Post-opc) 30–40 1–3 60–80 1–3
20–30 4–6 40–60 4–6
10–20 7–14 30–50 7–14
Surgery (minor)
Pre-op 40–80 50–80
Post-opd) 20–50 1–5 30–80 1–5

In this table, the desired peak factor levels of CFC replacement shown for treatment of hemorrhages at different anatomical sites represent the ranges in global practice patterns depending on available resources. Importantly, it should be recognized that the goal of such treatment is effective control of bleeding and should be the same everywhere in the world. Lower CFC replacement levels require much closer observation for effectiveness of bleeding control, with a potentially greater chance of requiring additional CFC replacement to achieve the target plasma level as well as the hemostatic and musculoskeletal outcomes.

a)May be longer if response is inadequate. b)Sometimes longer as secondary prophylaxis during physical therapy. c)The duration of treatment refers to sequential days post-surgery. Type of CFC and patient's response to CFC should be taken into account. d)Depending on procedure; the number of doses would depend on the half-life of the CFC used.

Abbreviations: CFC, clotting factor concentrate; NV, neurovascular.

Blood Res 2021;56:141~149 https://doi.org/10.5045/br.2021.2020289
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd